Saturday 17 October 2026
Export AEON’s income statement to Excel — free account
AEON Biopharma, Inc.
AEON Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.7%, free cash flow fell 76.9% and total debt fell 88.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.23
0.01
−4.17%
Follow AEON
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 242.64 | 36.14 | 0.38 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 1,056.96 | 1,236.24 | 42.48 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 3 | 10 | 5 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | 0 | 8 | (53) | (385) | 42 | (39) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | 0 | 8 | (53) | (385) | 42 | (39) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.04) | 86.67 | (27.23) | (745.41) | 77.74 | (3.95) | |||||
| Cash flow | — | — | — | — | 0.00 | (15.80) | (18.44) | (92.68) | (37.58) | (1.74) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.16) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | 0.00 | (15.80) | (18.60) | (92.68) | (37.58) | (1.74) | |||||
| Book value | — | — | — | — | 0.26 | (178.96) | (140.11) | (296.60) | (52.91) | (5.55) | |||||
| Shares, m | — | — | — | — | 0 | 0 | 2 | 1 | 1 | 10 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (36) | (48) | (20) | (17) | ||||
| Capex | — | — | — | — | — | — | 0 | — | — | 0 | |||||
| Free cash flow | — | — | — | — | — | (1) | (36) | (48) | (20) | (17) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 0 | (73) | (7) | (13) | (3) | ||||
| Total debt | — | — | — | — | 0 | — | 131 | — | 12 | 35 | |||||
| Net debt | — | — | — | — | 0 | 0 | 122 | (5) | 12 | 32 | |||||
| Shareholders’ equity | — | — | — | — | 0 | (17) | (270) | (153) | (29) | (55) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (8.89) | 5.92 | (36.53) | (4,365.11) | 841.19 | (901.45) | ||||
| ROIC | — | — | — | — | (5.45) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | (97.00) | 36.58 | 181.66 | (46.26) | 93.84 | |||||
Negative figures in brackets.
Charts ten years each
AEON Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CTXR Citius Pharmaceuticals, Inc. | $12.6M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| AEON AEON Biopharma, Inc. | $12.1M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | |
| ASBP Aspire-Lakewood Holdings, Inc. | $12.1M | 0.2× | — | — | n/m | −85.54% (below 0%: shrinking) | (47.70%) | (4,244.37%) | Compare |
| ACTU Actuate Therapeutics, Inc. | $12.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| PLUR Pluri Inc. | $11.9M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| INAB IN8bio, Inc. | $11.7M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $11.6M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $11.9M | — | — | −15.83% | — | −32.67% | 51.14% | (184.47%) |
AEON Biopharma, Inc. (AEON) key facts
- AEON Biopharma, Inc. (AEON) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, AEON traded at $0.23, a market capitalization of $12.1 million.
- Return on equity was 93.8% and debt-to-equity 0.00.
AEON Biopharma, Inc. (AEON) Latest News
No news at this impact. Lower the threshold for more.